CN105050597A - 增强干细胞治疗潜能的组合物和方法 - Google Patents

增强干细胞治疗潜能的组合物和方法 Download PDF

Info

Publication number
CN105050597A
CN105050597A CN201480015952.9A CN201480015952A CN105050597A CN 105050597 A CN105050597 A CN 105050597A CN 201480015952 A CN201480015952 A CN 201480015952A CN 105050597 A CN105050597 A CN 105050597A
Authority
CN
China
Prior art keywords
disease
antagonist
cell
compositions
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015952.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·范登博斯
B·雷尼什
J·申克
C·罗森鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Cologne GmbH
Original Assignee
Lonza Cologne GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Cologne GmbH filed Critical Lonza Cologne GmbH
Publication of CN105050597A publication Critical patent/CN105050597A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
CN201480015952.9A 2013-03-15 2014-03-13 增强干细胞治疗潜能的组合物和方法 Pending CN105050597A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159548.0A EP2777703B1 (en) 2013-03-15 2013-03-15 Compositions and methods for enhancing the therapeutic potential of stem cells
EP13159548.0 2013-03-15
PCT/IB2014/001248 WO2014140930A2 (en) 2013-03-15 2014-03-13 Compostions and methods for enhancing the therapeutic potential of stem cells

Publications (1)

Publication Number Publication Date
CN105050597A true CN105050597A (zh) 2015-11-11

Family

ID=47900872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015952.9A Pending CN105050597A (zh) 2013-03-15 2014-03-13 增强干细胞治疗潜能的组合物和方法

Country Status (10)

Country Link
US (4) US20160030482A1 (https=)
EP (1) EP2777703B1 (https=)
JP (1) JP6399410B2 (https=)
KR (1) KR102203925B1 (https=)
CN (1) CN105050597A (https=)
AU (1) AU2014229502B2 (https=)
BR (1) BR112015022565A2 (https=)
CA (1) CA2905650C (https=)
ES (1) ES2602078T3 (https=)
WO (1) WO2014140930A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108728410A (zh) * 2018-06-19 2018-11-02 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
CN110993051A (zh) * 2018-10-02 2020-04-10 卡西欧计算机株式会社 判定装置、判定方法以及记录介质

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7542258B2 (ja) * 2018-01-29 2024-08-30 中国科学院動物研究所 細胞の機械的恒常性を破壊し、組織器官の再生と修復を促進する方法、およびその使用
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN114144527A (zh) 2019-03-08 2022-03-04 联邦科学技术研究组织 固氮酶多肽在植物细胞中的表达

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101125146A (zh) * 2007-07-02 2008-02-20 中国药科大学 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂
US20100216181A1 (en) * 2009-02-20 2010-08-26 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
WO2012062819A2 (en) * 2010-11-09 2012-05-18 Lonza Cologne Gmbh Method for controlling binding of cells to a substrate
CN102940631A (zh) * 2012-11-02 2013-02-27 清华大学 Blebbistatin在促进干细胞存活和维持干细胞干性中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011176A2 (en) 2006-07-21 2008-01-24 Northwestern University Myosin light chain kinase inhibitor compounds, compositions and related methods of use
AU2009208391A1 (en) * 2008-01-31 2009-08-06 Monash University Methods of treating thromboembolic disorders
CN102395672A (zh) * 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101125146A (zh) * 2007-07-02 2008-02-20 中国药科大学 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂
US20100216181A1 (en) * 2009-02-20 2010-08-26 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
WO2012062819A2 (en) * 2010-11-09 2012-05-18 Lonza Cologne Gmbh Method for controlling binding of cells to a substrate
CN102940631A (zh) * 2012-11-02 2013-02-27 清华大学 Blebbistatin在促进干细胞存活和维持干细胞干性中的应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108728410A (zh) * 2018-06-19 2018-11-02 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
CN110993051A (zh) * 2018-10-02 2020-04-10 卡西欧计算机株式会社 判定装置、判定方法以及记录介质
CN110993051B (zh) * 2018-10-02 2023-11-07 卡西欧计算机株式会社 判定装置、判定方法以及记录介质

Also Published As

Publication number Publication date
BR112015022565A2 (pt) 2017-07-18
EP2777703A1 (en) 2014-09-17
EP2777703B1 (en) 2016-09-14
WO2014140930A3 (en) 2014-12-24
ES2602078T3 (es) 2017-02-17
KR102203925B1 (ko) 2021-01-19
AU2014229502A9 (en) 2016-06-16
KR20150131324A (ko) 2015-11-24
US20160030482A1 (en) 2016-02-04
AU2014229502A1 (en) 2015-09-24
WO2014140930A2 (en) 2014-09-18
JP6399410B2 (ja) 2018-10-03
US20200147142A1 (en) 2020-05-14
CA2905650A1 (en) 2014-09-18
JP2016510808A (ja) 2016-04-11
US20240316111A1 (en) 2024-09-26
US20180055888A1 (en) 2018-03-01
AU2014229502B2 (en) 2019-03-14
WO2014140930A9 (en) 2016-01-14
CA2905650C (en) 2022-08-23

Similar Documents

Publication Publication Date Title
US20240316111A1 (en) Compositions and methods for enhancing the therapeutic potential of stem cells
US10639335B2 (en) Pluripotent stem cell that induces repair and regeneration after myocardial infarction
Wang et al. Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction
JP5340941B2 (ja) 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用
Pokrovskaya et al. Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach
JP2010504083A5 (https=)
US20250115868A1 (en) Sequential application of macrophages for wound healing
CN104862281A (zh) 表达bFGF和PDGF-BB的重组载体修饰的间充质干细胞及其制备方法和用途
JP2012516853A (ja) 分化した内皮前駆細胞の治療的使用
KR20260042390A (ko) Ptx-3, timp1 및 bdnf를 발현하는 간엽줄기세포를 유효성분으로 포함하는 염증 질환 또는 통증의 예방 또는 치료용 약학 조성물
Marycz et al. Effects of steroids on the morphology and proliferation of canine and equine mesenchymal stem cells of adipose origin—in vitro research
JP2021155335A (ja) 変形性関節症の処置および／または予防方法
WO2014127232A2 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
US12133871B2 (en) Methods and compositions to enhance arteriogenesis
US20100209399A1 (en) Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
US11679178B2 (en) Methods for improving mechanical properties of a tissue or for regenerating an injured or diseased tissue
Sierra et al. Homofunctionality in Regeneration
Shahid In vitro modelling and treatment of laminitis using equine stem cells
US20150374741A1 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
WO2024048652A1 (ja) 骨および／または軟骨再生用の組成物、骨および／または軟骨の疾患の処置および／または予防用の組成物
Petchdee et al. Therapeutic Applications of Dental Pulp Stem Cells in Veterinary Medicine: A Case Report

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151111

WD01 Invention patent application deemed withdrawn after publication